Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Pancreatic Neoplasms 6Small Cell Lung Carcinoma 4Cholangiocarcinoma 4Stomach Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Thyroid Neoplasms 2Ovarian Neoplasms 2Neuroendocrine Tumors 2Carcinoma, Hepatocellular 2Biliary Tract Neoplasms 2Sarcoma 1Refractory Metastatic Digestive System Carcinoma 1Pulmonary Neuroendocrine Tumor 1Pancreatic Cancer Metastatic 1Osteosarcoma 1Neoplasms 1Neoplasm Metastasis 1NSCLC 1Locally Advanced Pancreatic Cancer 1Head and Neck Cancers - Salivary Gland 1Gallbladder Neoplasms 1Differentiated Thyroid Cancer 1Colorectal Neoplasms 1Carcinoma, Neuroendocrine 1Carcinoma 1Breast Neoplasms 1Appendiceal Neoplasms 1Advanced Solid Tumors 1Advanced Pancreatic Cancer 1Advanced Non-Small Cell Lung Cancer 1

Interventions

Docetaxel 5S 1 (combination) 2Carboplatin 2zimberelimab 1surufatinib 1quemliclustat 1pemigatinib 1nimotuzumab 1lorlatinib 1cemiplimab 1Vinorelbine 1Pemetrexed 1Paclitaxel 1Gene Expression Profiling 1Gemcitabine 1Erlotinib Hydrochloride 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Advanced Non-Small Cell Lung Cancer × surufatinib × Clear all
NCT04922658 2024-07-31

Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer

Affiliated Cancer Hospital & Institute of Guangzhou Medical University

Phase 2 Unknown
60 enrolled
Thoracic

Advanced Non-Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡